SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors express significant frustration and skepticism toward the Board's decision to accept an all-cash acquisition offer, which many feel drastically undervalues the company's cash position, core drug assets, and future growth potential. The community is actively debating the merits of the deal, with some shareholders organizing to oppose the tender offer and others seeking legal avenues to challenge what they characterize as an unethical 'fire sale' by management.

MMTec, Inc. engages in the holding of an equity interest in MM Future. It operates through the Gujia, MM Future and HC Securities and MM Global. The Gujia, MM Future and HC Securities segment provide market data services and consulting services. The MM Global segment is involved in introducing a broker that clears all transactions through a clearing broker dealer and earns commission income, placement agent services fee, and other related income from customers. The company was founded on January 4, 2018 and is headquartered in Hong Kong.

Mmtec Inc

Mmtec Inc is generating significant market interest as traders speculate on potential short squeeze dynamics and the company's efforts to maintain its NASDAQ listing status. Community discussions are heavily focused on the stock's extreme volatility and its tendency to mirror past microcap momentum plays, with participants actively debating the risks of delisting against the possibility of aggressive rallies.

Amtech Systems, Inc. engages in the manufacture of semiconductors and capital equipment. It operates through the Semiconductor and Material and Substrate segments. The Semiconductor segment involves the designing, manufacturing, selling, and servicing of thermal processing equipment and related controls for use by semiconductor manufacturers, and in electronics, automotive, and other industries. The Material and Substrate segment produces consumables and machinery for lapping and polishing materials, such as sapphire substrates, optical components, silicon wafers, and numerous types of crystal materials, ceramics, and metal components. The company was founded by Jong S. Whang in October 1981 and is headquartered in Tempe, AZ.

Amtech Systems Inc.

Amtech Systems is gaining momentum as investors eye its strategic role in the AI-driven semiconductor supply chain, specifically through its exposure to advanced packaging and wafer substrate fabrication. While the community remains optimistic about the company's long-term growth potential and turnaround narrative, discussions are increasingly balanced by caution regarding recent earnings performance and sector-wide cyclical risks.

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation–based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company’s offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

YD Bio Ltd.

YDES is currently garnering significant attention from retail traders due to its status as a recent Nasdaq uplisting with a remarkably low float, leading to discussions about potential volatility and short-squeeze setups. The community is closely monitoring the stock's price action alongside its associated warrants, debating whether current valuations present a mispricing opportunity or a speculative trap.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing satirical project that has transitioned onto the Solana network, with the community positioning it as a cultural successor to early Bitcoin lore. Supporters are actively discussing its 15-year history and perceived potential for generational wealth, while debates continue between those dismissing it as a meme-driven joke and those convinced it represents a unique opportunity in the current market cycle.

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

LENSAR Inc

LENSAR Inc. shares are under significant pressure following the mutual termination of its merger agreement with Alcon, a decision prompted by mounting regulatory opposition from the FTC. The community is actively debating the company's standalone future, weighing concerns over operational liquidity and intense market competition against the potential durability of its recurring revenue model and ALLY system adoption.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending due to its unique 'PvE' (Player-versus-Environment) narrative, which emphasizes long-term community conviction over short-term speculative trading. Supporters are actively highlighting the project's 'Airlock' mechanismwhere nearly half of the supply is voluntarily lockedas proof of a committed, cult-like movement that is actively outperforming typical market volatility.

Ethereum Classic

Ethereum Classic is experiencing renewed community focus as investors speculate on a long-awaited breakout, with many sentiment-driven discussions highlighting the contrast between the token's historical performance and its current suppressed price action. Traders are actively debating the timing of a potential trend reversal, frequently citing broader crypto market catalysts and comparing its utility to other established proof-of-work assets.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently rallying on optimism surrounding potential ETF approval and its dominant position as a leading decentralized perpetual exchange. The community is actively discussing its rapid growth in trading volume and its role as a key infrastructure player in the broader decentralized finance ecosystem.

Maulcoin

Maulcoin is trending as the community celebrates the restoration of its ticker symbol and anticipates the upcoming release of a price chart. Supporters are actively engaging in community-led growth strategies, framing the project as an honest, long-term alternative to typical pump-and-dump meme coins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares Rise as Biotech Pivots Toward AI-Driven Pharmaceutical Automation

Pharmaceutical manufacturing is one of the most heavily regulated industries in the world. Every batch, every deviation, and every cleaning record must be documented and defensible under audit. This process has traditionally been manual, slow, and expensive. Companies capable of automating these workflows with AI stand to save significant time while reducing compliance risk. Today, one clinical-stage biotech announced a strategic deal to bring that automation to the physical factory floor.&nbsp;Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on the ...

Micro-Cap Stuns Market with Billion-Dollar Pipeline Valuation

It&#8217;s not often that a micro-cap company with a market value of around $40 million announces a third-party valuation of its drug development pipeline at $1.7 billion, 45% of which it owns. But that&#8217;s exactly what was revealed in a press release this morning. As expected, the stock reacted swiftly and rallied on the news.As mentioned, shares of Oncotelic Therapeutics <a href="https://www.allpennystocks.com/stockquote/OTLC" target="_blank">(OTCQB: OTLC)</a> are surging on news that the company announced a major milestone after its joint venture partner, GMP Bio, completed an independent third-party valuation of its drug development pipeline. The assessment, performed by Frost &amp; Sullivan (Hong Kong), values the pipeline at roughly $1.7 billion, translating to an estimated $765 million potential value for Oncotelic based on its 45% ownership stake. The company noted that this figure is forward-looking and non-binding, and it does not reflect fair value under U.S. GAAP. To support upcoming financial disclosures, a separate ASC-compliant valuation is already underway. If that analysis indicates a materially higher carrying value, Oncotelic may adjust future financial statements to reflect its increased minority interest, potentially boosting total assets and shareholder equity, pending the outcome of the review and applicable accounting standards.The joint venture has made significant progress across its therapeutic programs, including moving OT-101 into a Phase 3 PDAC trial and multiple Phase 2 combination studies. Meanwhile, GMP Bio is actively expanding its Deciparticle&#8482; nanomedicine platform, with several candidates advancing toward clinical development. Its San Diego GMP-licensed manufacturing facility is now fully operational and ready to support upcoming trials. Looking ahead, the JV is exploring a possible IPO on the Hong Kong Stock Exchange targeted for late 2026. While market conditions and regulatory approval will ultimately dictate the timing, Oncotelic views the strong pipeline valuation as a key indicator of the strategic value behind the potential offering.&#8220;This represents one of the most significant milestones in Oncotelic&#8217;s history,&#8221; said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics. &#8220;The independent valuation recognizes the multi-year scientific and clinical progress achieved through our GMP Bio joint venture and affirms the long-term potential of OT-101 and our Deciparticle&#8482; nanomedicine platform.&#8221;Shares of OTLC are currently trading up 26.15% at $0.09524 in mid-morning trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4012/micro-cap-stuns-market-with-billion-dollar-pipeline-valuation'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

OTLC
Oncotelic Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OTLC News

OTLCOncotelic Therapeutics Inc